Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study

Biomedicines

PierluigiBenedetti Panici¹  Violante Di Donato¹  Roberto Angioli²  Carlo De Cicco Nardone²  Corrado Terranova²  Daniela Luvero²  Camilla Dionisi²  Federica Guzzo²  Francesco Plotti²  Martina Bartolone²  Silvia Fabris³  Domenico Benvenuto³  Massimo Ciccozzi³ 

[1] Department of Gynecology, Obstetrics and Urology, Policlinico Umberto I, ‘‘Sapienza’’ University of Rome, 00161 Rome, Italy;Department of Obstetrics and Gynecology, University ‘‘Campus Bio-Medico’’ of Rome, Via Alvaro del Portillo, 200 - 00128 Rome, Italy;Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, Italy;

关键词: ovarian cancer;    HE4;    BRCA;    chemotherapy response;   

DOI  :  10.3390/biomedicines9010055

来源: DOAJ

【 摘 要 】

Even though 80% of patients with High-Grade Serous Ovarian Cancer respond to standard first-line chemotherapy, a majority of them could relapse in the following five years due to a resistance to platinum. Human Epididymis protein 4 (HE4) is one of the most promising markers in predicting platinum therapy response. This pilot study aims to evaluate the potential role of HE4 value in predicting chemotherapy response in BRCA mutated patients and in BRCA wild-type (non-mutated) ones. We selected 69 patients, affected by High-Grade Serous Ovarian Cancer, and optimally debulked and submitted to standard chemotherapy protocols. HE4 was dosed during every chemotherapy course. Patients were classified as platinum-resistant and platinum-sensitive. According to BRCA mutation test, patients were further divided into BRCA wild-type (53 patients), and BRCA mutated (16 patients). 35 patients out of 69 (52%) were platinum-sensitive (recurrence > 12 months), while 33 patients (48%) were platinum-resistant (recurrence < 12 months). Thus, in the total population, HE4 performed as a marker of chemosensitivity with a sensibility of 79% and a specificity of 97%. In the BRCA WT group, 23 patients out of 53 (43%) were platinum-sensitive, while 30 patients out of 53 (57%) were platinum-resistant. In the BRCA WT group, HE4 performed as a predictive marker of chemosensitivity with a sensibility of 80% and a specificity of 100%. In the BRCA mutated group, 13 patients out of 16 (82%) were platinum-sensitive, while 3 patients (18%) were platinum-resistant. In the BRCA mutated group, HE4 performed as a predictive marker of chemosensitivity in all patients. The ability to detect platinum-resistant patients before tumor relapse probably could open new therapeutic scenarios.

【 授权许可】

Unknown